Despite germ cell tumors (GCTs) responding to cisplatin-based chemotherapy at a high rate, a subset of patients does not respond to treatment and have significantly worse prognosis. The biological mechanisms underlying the resistance remain unknown. In this study, by using two TGCT cell lines that have acquired cisplatin resistance after chronic exposure to the drug, we identified some key proteins and mechanisms of acquired resistance. We show that cisplatin-resistant cell lines had a non-homologous end-joining (NHEJ)-less phenotype. This correlated with a reduced basal expression of TP53-binding protein 1 (53BP1) and DNA-dependent protein kinase (DNA-PKcs) proteins and reduced formation of 53BP1 foci after cisplatin treatment. Consistent with these observations, modulation of 53BP1 protein expression altered the cell line's resistance to cisplatin, and inhibition of DNA-PKcs activity antagonized cisplatin cytotoxicity. Dampening of NHEJ was accompanied by a functional increase in the repair of DNA double-strand breaks (DSBs) by the homologous recombination repair pathway. As a result, cisplatin-resistant cells were more resistant to PARP inhibitor (PARPi) monotherapy. Moreover, when PARPi was given in combination with cisplatin, it exerted an additive/synergistic effect, and reduced the cisplatin dose for cytotoxicity. These results suggest that treatment of cisplatin-refractory patients may benefit from low-dose cisplatin therapy combined with PARPi.
Cancers. 2021 Feb 13*** epublish ***
Cinzia Caggiano, Francesca Cavallo, Teresa Giannattasio, Gioia Cappelletti, Pellegrino Rossi, Paola Grimaldi, Darren R Feldman, Maria Jasin, Marco Barchi
Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy., Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA., Developmental Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.